Balancing RCTs and RWE in Evidence Strategies for Digital Health Tools Balancing RCTs and RWE in Evidence Strategies for Digital Health Tools As the landscape of digital health evolves, demonstrating the safety and effectiveness of Software as a Medical Device (SaMD) has become increasingly complex. Regulatory bodies, primarily the U.S. Food and Drug Administration (FDA), are emphasizing the integration of Real-World Data (RWD) and Real-World Evidence (RWE) into clinical evaluation strategies. This tutorial aims to provide a step-by-step guide for regulatory, clinical, and quality leaders in the digital health sphere to effectively balance randomized controlled trials (RCTs) and RWE in…

Templates for RWE Sections in SaMD and Digital Therapeutic Submissions The integration of real-world data (RWD) and real-world evidence (RWE) into the regulatory submission process for Software as a Medical Device (SaMD) and digital therapeutics is becoming increasingly pivotal. The FDA, as part of its digital health strategy, recognizes the value and necessity of RWD and RWE in supporting regulatory submissions. This article serves as a step-by-step guide for regulatory professionals in the digital health sector, offering insights into effectively incorporating RWD and RWE into SaMD and digital therapeutic submissions. By understanding the regulatory framework and employing standardized templates, stakeholders…

Global Perspectives on Digital Evidence in EU MDR and HTA Assessments The increasing integration of digital health technologies, including Software as a Medical Device (SaMD), applications, and artificial intelligence (AI) solutions, has created an urgent need for regulatory frameworks that accommodate new sources of evidence. This comprehensive guide offers a detailed examination of real-world data (RWD), real-world evidence (RWE), and digital endpoints as they pertain to FDA submissions. It also positions EU Medical Device Regulation (MDR) and Health Technology Assessment (HTA) within this evolving landscape. By aligning our understanding with regulatory expectations, digital health innovators can effectively navigate the complex…

Engaging FDA Early on Digital Endpoints and RWE Plans for SaMD The advent of Software as a Medical Device (SaMD) has transformed the landscape of healthcare and the regulatory frameworks underpinning evaluation and approval processes. Engaging the FDA early in the development of digital endpoints and plans for Real-World Evidence (RWE) is pivotal for ensuring compliance, gaining insights, and refining your submission strategy. This comprehensive tutorial aims to guide digital health, regulatory, clinical, and quality professionals through the essential steps of navigating FDA regulations on RWD, RWE, and digital endpoints effectively. Understanding the Regulatory Frameworks The first step in engaging…

Case Studies of FDA Authorized Digital Therapeutics and Their Evidence The rise of digital therapeutics (DTx) has transformed the healthcare landscape, especially in the realm of mental health, chronic disease management, and rehabilitation. As these solutions gain traction, understanding the regulatory framework surrounding their development and validation is crucial for clinical, regulatory, and quality leaders in digital health. This article serves as a comprehensive guide to the FDA authorization process for digital therapeutics, providing insights through case studies and delineating effective strategies for clinical evaluation and validation. Understanding Digital Therapeutics and Regulatory Landscape Digital therapeutics are evidence-based therapeutic interventions delivered…

Validation Strategies for DTx Usability, Adherence and Engagement Metrics The increasing integration of digital therapeutics (DTx) into healthcare necessitates a comprehensive understanding of the regulatory landscape surrounding their clinical evaluation and validation. This tutorial aims to guide digital health, regulatory, clinical, and quality leaders through the step-by-step processes of establishing effective validation strategies for DTx, focusing on usability, adherence, and engagement metrics. Understanding Clinical Evaluation and Validation of Digital Therapeutics (DTx) To successfully navigate the regulation of DTx, it is essential to comprehend the fundamental principles of clinical evaluation and validation. The FDA defines DTx as software that provides therapeutic…

Endpoints and Outcome Measures Suited to Behavioural and Software Therapies The regulatory landscape for digital therapeutics (DTx) continues to evolve, and defining the appropriate endpoints and outcome measures for clinical evaluation and validation is crucial to the success of these interventions. This tutorial will provide a comprehensive, step-by-step guide for digital health leaders in the United States, the United Kingdom, and the European Union to understand and implement effective strategies for measuring and validating DTx. Understanding Digital Therapeutics (DTx) Digital therapeutics are evidence-based therapeutic interventions delivered via software to prevent, manage, or treat medical disorders or diseases. The rise of…

Designing Pivotal Trials for DTx Products Targeting Chronic Conditions The landscape of healthcare is rapidly evolving with the emergence of Digital Therapeutics (DTx) products. These innovative solutions play a crucial role in managing chronic conditions through behavioral interventions and technology. As a part of this evolution, it is imperative for digital health professionals to understand how to effectively design clinical trials that validate the efficacy and usability of DTx products. This article provides a comprehensive, step-by-step guide to assist regulatory, clinical, and quality leaders in developing pivotal trials for DTx targeting chronic conditions. Understanding Digital Therapeutics (DTx) Digital Therapeutics are…

Clinical Evaluation Frameworks for Prescription Digital Therapeutics (DTx) The ever-evolving landscape of digital health has brought forth innovative solutions such as prescription digital therapeutics (DTx). These software-based interventions require rigorous frameworks for clinical evaluation and validation to ensure their effectiveness and safety. This article provides a comprehensive step-by-step guide to navigating the clinical evaluation processes for DTx in compliance with US FDA regulations, while also drawing comparisons with EU and UK frameworks where necessary. Understanding Clinical Evaluation for DTx Clinical evaluation forms the backbone of the development process for prescription DTx, directly influencing their approval and monitoring. Clinical evaluation is…

Designing Sham Control and Blinding Approaches for DTx Trials Designing Sham Control and Blinding Approaches for DTx Trials Digital therapeutics (DTx) are transforming self-care and healthcare management by effectively addressing various health conditions through software-driven interventions. However, conducting clinical trials for DTx to validate their efficacy and safety presents unique challenges. In this tutorial, we focus on the importance of sham control and blinding approaches in DTx trials, offering a step-by-step guide for digital health, regulatory, clinical, and quality leaders involved in software as a medical device (SaMD), applications, and artificial intelligence solutions. Understanding the Necessity of Blinding and Sham…